Related Experiment Video
Updated: Aug 28, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
The evolution of dual antiplatelet therapy in patients with coronary artery disease
Moa Simonsson1, Stefan James2, Jurriën M Ten Berg3,4
1Department of Medicine Solna, Division of Cardiology, Karolinska Institutet, D1:04, SE-171 76, Stockholm, Sweden.
Abstract:
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor has been the mainstay of therapy for acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) following percutaneous coronary intervention (PCI) for more than two decades. Over this period, numerous trials have evaluated different antiplatelet strategies, initially focusing on more effective and prolonged regimens, and more recently on decreasing the intensity or duration of DAPT. Despite a wealth of accumulated evidence, the optimal antiplatelet strategy-including the ideal agent, combination, or treatment duration-remains a subject of active debate. This review summarizes the evolution of antiplatelet therapy, with particular emphasis on randomized controlled trials of DAPT in patients with ACS or CCS undergoing PCI.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Angina IV: Management
Atherosclerosis III: Management
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations